CARLOS SOLIS: Open Payments
NPI 1922657584 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$738 in 32 payments from 11 companies in 2025. Trend: 2023 $435 · 2024 $391 · 2025 $738
Food & beverage: $738
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $129 |
| Merck Sharp & Dohme LLC | 4 | $123 |
| ABBVIE INC. | 6 | $105 |
| Baxter Healthcare | 2 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Madrigal Pharmaceuticals | 4 | $67 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| Genentech USA, Inc. | 2 | $46 |
| La Jolla Pharmaceutical Company | 1 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $26 |
Products named: XIFAXAN, ZERBAXA, TEFLARO, PERCLOT, LIVTENCITY, REZDIFFRA, TERLIVAZ, Tecentriq.
Industry payments across TX — which companies pay providers there.
